160194-39-8

Basic information

• Product Name: 2-{5-[(1H-1,2,4-TR IAZOOL-1-YL)METHYL]INDOOL-3-YL}ETHAAN-1-OL
• Synonyms: 2-{5-[(1H-1,2,4-TR IAZOOL-1-YL)METHYL]INDOOL-3-YL}ETHAAN-1-OL;2-[5-(1,2,4-Triazol-1-ylmethyl)-1H-indol-3-yl]ethanol;2-(6-((1H-1,2,4-triazol-1-yl)methyl)-1H-indol-3-yl)ethanol;5-(1H-1,2,4-triazol-1-ylmethyl)-1H-Indole-3-ethanol
• CAS NO: 160194-39-8
• Molecular Formula: C₁₃H₁₄N₄O
• Molecular Weight: 242.27646
• Mol File: 160194-39-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 545.458 °C at 760 mmHg
• Flash Point: 283.683 °C
• Appearance: /
• Density: 1.35
• PKA: 14.95±0.10(Predicted)
• CAS DataBase Reference: 2-{5-[(1H-1,2,4-TR IAZOOL-1-YL)METHYL]INDOOL-3-YL}ETHAAN-1-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-{5-[(1H-1,2,4-TR IAZOOL-1-YL)METHYL]INDOOL-3-YL}ETHAAN-1-OL(160194-39-8)
• EPA Substance Registry System: 2-{5-[(1H-1,2,4-TR IAZOOL-1-YL)METHYL]INDOOL-3-YL}ETHAAN-1-OL(160194-39-8)

Safety Data

• Hazardous Substances Data: 160194-39-8(Hazardous Substances Data)

Usage

Uses

5-(1H-1,2,4-Triazol-1-ylmethyl)-1H-indole-3-ethanol is an intermediate in the synthesis of Rizatriptan Benzoate (R545000); a selective serotonin 5-HT1D receptor agonist and a potential anti-migraine drug.

Upstream product

• 119192-10-8 4-(1H-1,2,4-triazol-1-ylmethyl)aniline 
• 160194-28-5 1-triethylsilanyl-4-(triethylsilanyloxy)but-1-yne 
• 160194-26-3 4-((1H-1,2,4-triazol-1-yl)methyl)-2-iodobenzenamine 

Downstream Products

• 144034-80-0 rizatriptan 
• 145202-66-0 rizatriptan benzoate 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISEASES

This invention relates to CXCR4 inhibitors and their use in treating and/or preventing a variety of angiogenic, microvascular and ocular disorders including primary indications for diabetic retinopathy, macular degeneration (such as wet or neovascular age

Azetidine, pyrrolidine and piperidine derivatives

A class of substituted azetidine, pyrrolidine and piperidine derivatives are selective agonists of 5-HT1 -like receptors, being potent agonists of the human 5-HT1Dα receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT1Dα receptor subtype relative to the 5-HT1Dβ subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT1D receptor agonists.